U.S. FDA accepts Takeda’s biologics license application for a subcutaneous formulation of vedolizumab (Entyvio) for maintenance therapy in moderately to severely active ulcerative colitis

Takeda

9 May 2019 - An additional treatment modality would provide more flexibility in how patients receive vedolizumab, a biologic with a gut-selective mode of action.

Takeda Pharmaceutical Company today announced that the U.S. FDA has accepted for review a biologics license application for a subcutaneous formulation of vedolizumab for maintenance therapy in adults with moderately to severely active ulcerative colitis. Takeda proposes to make vedolizumab subcutaneous available in both pre-filled syringe and pen options.

The application is based on the pivotal VISIBLE 1 phase 3 study, which assessed the safety and efficacy of a subcutaneous formulation of vedolizumab as maintenance therapy in 216 adult patients with moderately to severely active ulcerative colitis who achieved clinical response at week 6 following two doses of open-label vedolizumab intravenous therapy at weeks 0 and 2.

Read Takeda press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Dossier